Subscribe to our Newsletters !!
The life cycle of malaria is a complex process inv
METTLER TOLEDO announces the launch of four new la
Relevant codes should be used when coding fibromya
Sun Pharma, a prominent pharmaceutical enterprise
Principal Component Analysis (PCA) is a powerful t
It is important to understand that natural remedie
In a world constantly in motion, Microbioz India r
One of the enduring problems that this United States Pharmacopeia (USP) is the need to establish guidelines for testing standards that represent common use. Dry powder inhalers that are passive (DPIs) depend solely on the inhalation effort produced by the patient in order to generate an aerosol that can be breathed. In the past, DPIs have been used to administer medication to aid in the immediate treatment or alleviation of chronic obstructive pulmonary disease (COPD) as well as asthma. Patients suffering from one or the other of these conditions, typically, suffer from diminished respiratory function, and may be less capable to breathe vigorously through an aerodynamically resistive DPI.
In this webinar you will learn:
Understand the Pharmacopoeial requirements and why these are important Find out all about the basics of OINDPs testing Learn all about DDU and APSD testing Understand the equipment that is key for your testing
Date: February 4th 2022
Time: 03:00 PM IST onwards
Speaker: Anna Sipitanou, Head of Business Development at Copley Scientific
Click here for registrations: https://meet.zoho.in/eEgFqW1LdH
To know more visit: https://www.copleyscientific.com/multiproducts/tbf-100i/
For more information: support@microbiozindia.com